Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.
暂无分享,去创建一个
Daniel G Haller | P. Catalano | J. Berlin | A. Benson | J. Kugler | D. Haller | Jordan D Berlin | John W Kugler | Paul Catalano | James P. Thomas | James P Thomas | Al Bowen Benson
[1] D. Sargent,et al. Phase III evaluation of octreotide versus chemotherapy with 5-fluorouracil or 5-fluorouracil plus leucovorin in advanced exocrine pancreatic cancer: a North Central Cancer Treatment Group study. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[2] A. Rosemurgy,et al. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] H. Friess,et al. Activity of Gemcitabine and Continuous Infusion Fluorouracil in Advanced Pancreatic Cancer , 2000, Oncology.
[4] L. Fein,et al. Phase II trial of gemcitabine (GEM), 5-Fluoruracil (5-FU) and leucovorin (LV) in advanced pancreatic cancer (PC) , 1999 .
[5] P. Tagliaferri,et al. Gemcitabine combined with continuous infusion 5-fluorouracil in advanced and symptomatic pancreatic cancer: a clinical benefit-oriented phase II study , 2000, British Journal of Cancer.
[6] Taylor Murray,et al. Cancer Statistics, 2001 , 2001, CA: a cancer journal for clinicians.
[7] M. Hidalgo,et al. Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] John D. Roberts,et al. Leucovorin, 5-fluorouracil, and gemcitabine: A phase I study , 2004, Investigational New Drugs.
[9] D. V. Von Hoff,et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] J. Grem,et al. Cytotoxicity and DNA fragmentation associated with sequential gemcitabine and 5-fluoro-2'-deoxyuridine in HT-29 colon cancer cells. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[11] J. Berlin,et al. A phase I study of gemcitabine, 5-fluorouracil and leucovorin in patients with advanced, recurrent, and/or metastatic solid tumors , 1998, Investigational New Drugs.
[12] D. Huhn,et al. Phase I trial of gemcitabine (Gemzar), 24 h infusion 5-fluorouracil and folinic acid in patients with inoperable pancreatic cancer. , 1999, Anti-cancer drugs.
[13] M. Buyse,et al. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] J. Berlin,et al. A Phase II Study of Gemcitabine and 5-Fluorouracil in Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study (E3296) , 2000, Oncology.
[15] A. Harris,et al. Phase II study of gemcitabine in patients with advanced pancreatic cancer. , 1996, British Journal of Cancer.
[16] S. Barni,et al. A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD) , 1999, British Journal of Cancer.
[17] N. Mantel. Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.
[18] D. Cox. Regression Models and Life-Tables , 1972 .